Seeking babies aged 5 to 24 months old for a study of an mRNA vaccine to prevent respiratory syncytial virus (RSV).
Participants in this study will either get one of two doses of the experimental mRNA vaccine or a placebo (looks like the vaccine but contains no medicine). The vaccines will be given as an injection three times over a period of 4 months. After the third and final injection, there will be periodic follow-up visits over 2 years.
What we're hoping for
We are studying whether an mRNA vaccine is safe and effective in preventing respiratory syncytial virus (RSV) infection in babies aged 5 to 24 months.
ClinicalTrials.gov Identifier: NCT05743881